Table 1 Clinical characteristics of the patients in the discovery study in survivors and non-survivors at 28 days
From: Circulating neutrophil counts and mortality in septic shock
Total (n = 195) | Survivors (n = 125) | Non-survivors (n = 70) | P | |
|---|---|---|---|---|
Patient details | ||||
Gender (male) | 125 (64.1%) | 79 (63.2%) | 46 (65.7%) | NS |
Age (years) | 71.6 ± 11.1 | 70.2 ± 11.1 | 74.2 ± 10.7 | 0.014 |
Hypertension | 109 (55.9%) | 71 (56.8%) | 38 (54.3%) | NS |
Cardiovascular disease | 87 (44.6%) | 54 (43.2%) | 33 (47.1%) | NS |
Cancer | 44 (22.5%) | 21 (16.8%) | 23 (32.8%) | 0.010 |
COPD | 33 (16.9%) | 24 (19.2%) | 9 (12.8%) | NS |
Diabetes | 31 (15.9%) | 24 (19.2%) | 7 (10%) | NS |
Obesity | 32 (16.4%) | 21 (16.8%) | 11 (15.7%) | NS |
Smoker | 27 (13.8%) | 17 (13.6%) | 10 (14.2%) | NS |
Chronic renal failure | 26 (13.3%) | 15 (12.0%) | 11 (15.7%) | NS |
Alcohol abuse | 12 (6.1%) | 8 (6.4%) | 4 (5.7%) | NS |
Inmunosuppression | 9 (4.6%) | 5 (4.0%) | 4 (5.7%) | NS |
Hepatic disease | 6 (3.1%) | 4 (3.2%) | 2 (2.8%) | NS |
Clinical status at admission | ||||
APACHE II | 14.7 ± 5.9 | 13.9 ± 5.8 | 16.2 ± 5.9 | 0.013 |
Mechanical ventilation | 134 (68.7%) | 83 (66.4%) | 51 (72.9%) | NS |
OARF | 41 (21.0%) | 19 (15.2%) | 22 (31.4%) | 0.008 |
Presumed source of infection | ||||
Digestive system | 115 (58.9%) | 76 (60.8%) | 39 (55.7%) | NS |
Respiratory system | 19 (9.7%) | 14 (11.2%) | 5 (7.1%) | NS |
Central nervous system | 20 (10.2%) | 14 (11.2%) | 6 (8.5%) | NS |
Urinary system | 10 (5.1%) | 5 (4.0%) | 5 (7.1%) | NS |
Endocardium | 7 (3.5%) | 5 (4.0%) | 2 (2.8%) | NS |
Catheter | 34 (17.4%) | 26 (20.8%) | 8 (11.4%) | NS |
Wound/skin, soft tissue | 28 (14.3%) | 20 (16.0%) | 8 (11.4%) | NS |
Other/unknown | 55 (28.2%) | 35 (28.0%) | 20 (28.5%) | NS |
Type of surgery | ||||
Abdominal | 99 (50.7%) | 56 (44.8%) | 43 (61.4%) | 0.030 |
Cardiac | 71 (36.4%) | 54 (43.2%) | 17 (24.3%) | |
Other | 25 (12.8%) | 15 (12.0%) | 10 (14.3%) | |
Urgent surgery | ||||
Yes | 130 (66.6%) | 77 (61.6)% | 53 (75.7%) | 0.045 |
Documented microbial agent | ||||
Gram-negative | 67 (41.6%) | 48 (44.4%) | 19 (35.8%) | NS |
Gram-positive | 68 (42.2%) | 47 (43.5%) | 21 (39.6%) | NS |
Fungi | 24 (14.9%) | 16 (14.8%) | 8 (15.1%) | NS |
Laboratory data | ||||
Bilirubin (mg/dL) | 1.4 ± 1.3 | 1.5 ± 1.4 | 1.2 ± 1.0 | NS |
Glycemia (mg/dL) | 166.4 ± 65.1 | 165.4 ± 58.3 | 168.2 ± 76.0 | NS |
Procalcitonin (ng/mL) | 19.3 ± 32.5 | 16.5 ± 28.6 | 24.3 ± 38.1 | NS |
CRP (mg/mL) | 231.8 ± 119.2 | 221.9 ± 106.6 | 249.4 ± 138.1 | NS |
INR | 1.7 ± 0.9 | 1.6 ± 0.9 | 1.7 ± 0.8 | NS |
Platelets (×103/μl) | 190.2 ± 140.0 | 196.9 ± 143.5 | 178.2 ± 133.5 | NS |
Leukocytes (×103/μl) | 16.3 ± 10.1 | 16.4 ± 9.0 | 16.2 ± 11.7 | NS |
Monocytes (×103/μl) | 0.7 ± 0.4 | 0.7 ± 0.4 | 0.6 ± 0.5 | NS |
Lymphocyte (×103/μl) | 1.1 ± 0.7 | 1.1 ± 0.8 | 1.0 ± 0.6 | NS |
Neutrophils (×103/μl) | 14.4 ± 9.4 | 14.4 ± 8.4 | 14.3 ± 11.1 | NS |
Basophils (×103/μl) | 0.1 ± 0.0 | 0.1 ± 0.1 | 0.1 ± 0.0 | NS |
Eosinophils (×103/μl) | 0.1 ± 0.0 | 0.1 ± 0.0 | 0.1 ± 0.0 | NS |